Renin Inhibition with Aliskiren: A Decade of Clinical Experience
AbstractThe renin-angiotensin-aldosterone system (RAAS) plays a key role in the pathophysiology of arterial hypertension as well as in more complex mechanisms of cardiovascular and renal diseases. RAAS-blocking agents like angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers, have long been key components in the treatment of essential hypertension, heart failure, diabetic nephropathy, and chronic kidney disease, showing benefits well beyond blood pressure reduction. Renin blockade as the first step of the RAAS cascade finally became possible in 2007 with the approval of aliskiren, the first orally active direct renin inhibitor available for clinical use and the newest antihypertensive agent on the market. In the last decade, many clinical trials and meta-analyses have been conducted concerning the efficacy and safety of aliskiren in comparison to other antihypertensive agents, as well as the efficacy and potential clinical use of various combinations. Large trials with cardiovascular and renal endpoints attempted to show potential benefits of aliskiren beyond blood pressure lowering, as well as morbidity and mortality outcomes in specific populations such as diabetics, heart failure patients, and post-myocardial infarction individuals. The purpose of this review is to present the currently available data regarding established and future potential clinical uses of aliskiren. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Pantzaris, N.-D.; Karanikolas, E.; Tsiotsios, K.; Velissaris, D. Renin Inhibition with Aliskiren: A Decade of Clinical Experience. J. Clin. Med. 2017, 6, 61.
Pantzaris N-D, Karanikolas E, Tsiotsios K, Velissaris D. Renin Inhibition with Aliskiren: A Decade of Clinical Experience. Journal of Clinical Medicine. 2017; 6(6):61.Chicago/Turabian Style
Pantzaris, Nikolaos-Dimitrios; Karanikolas, Evangelos; Tsiotsios, Konstantinos; Velissaris, Dimitrios. 2017. "Renin Inhibition with Aliskiren: A Decade of Clinical Experience." J. Clin. Med. 6, no. 6: 61.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.